年龄与衰弱状态对每周一次塞利尼索、硼替佐米和地塞米松方案疗效与耐受性的影响
该研究为BOSTON 3期试验的事后亚组分析,按年龄(<65岁和≥65岁)及衰弱状态(非衰弱和衰弱)比较XVd与Vd方案。在≥65岁患者中,XVd较Vd显著提高ORR、≥VGPR、PFS和OS;在衰弱患者中XVd显示PFS和OS获益趋势;XVd在≥65岁和衰弱患者中≥2级周围神经病变发生率更低。
要点
- 在≥65岁复发难治多发性骨髓瘤患者中,XVd较Vd显著改善ORR、≥VGPR、PFS和OS。
- 在衰弱患者中,XVd较Vd显示出PFS和OS获益趋势。
- XVd在≥65岁和衰弱患者中≥2级周围神经病变发生率显著低于Vd。
核心结论
- XVd在<65岁和≥65岁以及非衰弱和衰弱既往治疗的多发性骨髓瘤患者中均安全有效。
研究设计与样本
- BOSTON 3期试验的回顾性亚组分析,为多中心、前瞻性、随机试验的事后分析,按年龄(<65岁和≥65岁)及衰弱状态(非衰弱和衰弱)分组比较XVd与Vd。
主要发现
- <65岁患者中观察到ORR和TTNT显著改善,非衰弱患者中观察到PFS、ORR、≥VGPR和TTNT显著改善。
- ≥3级TEAE在老年与年轻患者之间、衰弱与非衰弱患者之间均未观察到更频繁发生。
临床怎么用
- 对于≥65岁或衰弱的既往治疗多发性骨髓瘤患者,XVd方案可考虑作为治疗选择,其疗效优于Vd且周围神经病变发生率更低。
局限性
- 该分析为回顾性亚组分析,统计效力有限,尤其衰弱亚组中PFS和OS的获益仅为趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and ≥65 years, nonfrail and frail). Patients ≥65 years with XVd had higher ORR (OR 1.77, p = .024), ≥VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, ≥VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade ≥ 2 peripheral neuropathy in ≥65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade ≥3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and ≥65 and in nonfrail and frail patients with previously treated MM.
引用
- Auner HW, Gavriatopoulou M, Delimpasi S, et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021. PMID: 33755235. doi:10.1002/ajh.26172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。